United States · FDA National Drug Code directory
RIVASTIGMINE TARTRATE
A source-listed medicine record.
Factual source checks only. This page is not a clinically reviewed monograph. Historical or discontinued records may be included; listing does not confirm approval, current availability or pharmacy stock.
Medicine identity
- Source reference
- 33342-091_3ac90f1e-d2a5-4645-972b-0d627e4cc860
- Product NDC
- 33342-091
- Form
- CAPSULE
- Composition / generic term
- RIVASTIGMINE TARTRATE
- Labeler
- Macleods Pharmaceuticals Limited
- Marketing category
- ANDA
- Marketing start / end (source format)
- 20140902
- Source listing expiry
- 20261231
Source-listed ingredients
- RIVASTIGMINE TARTRATE — 4.5 mg/1
These values do not establish equivalence or a dose recommendation.
Packages
- 3 BLISTER PACK in 1 BOX, UNIT-DOSE (33342-091-06) / 10 CAPSULE in 1 BLISTER PACK · 33342-091-06
- 60 CAPSULE in 1 BOTTLE (33342-091-09) · 33342-091-09
- 10 BLISTER PACK in 1 BOX, UNIT-DOSE (33342-091-12) / 10 CAPSULE in 1 BLISTER PACK · 33342-091-12
- 500 CAPSULE in 1 BOTTLE (33342-091-15) · 33342-091-15
Source and coverage
Open FDA National Drug Code directory →
Snapshot retrieved: 2026-09-17. This is the acquisition date, not a medical review date.
Clinical information, images and comparisons appear only when separately reviewed for this record. Coverage may be incomplete. Ask a pharmacist or clinician about your treatment.
Browse United States records →